Ocugen (OCGN) Retained Earnings (2014 - 2026)
Ocugen's (OCGN) quarterly Retained Earnings came in at $429.5 million in Q1 2026, up 220.81% YoY from $133.9 million in Q1 2025, and up 704078.69% on a QoQ basis from $61000.0 in Q4 2025.
Ocugen (OCGN) Retained Earnings (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Retained Earnings data on file, last reported at $429.5 million in Q1 2026.
- Quarterly Retained Earnings rose 220.81% year-over-year to $429.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $429.5 million (up 220.81% YoY) and the FY2025 annual result came in at $61000.0, up 27.08% from the prior year.
- Retained Earnings rose to $429.5 million in Q1 2026, from $61000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $429.5 million in Q1 2026 to a low of -$390.4 million in Q3 2025.
- A 5-year average of -$122.4 million and a median of -$200.7 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings sank 1697491.3% — and 2026, when it soared 220.81%.
- Tracing OCGN's Retained Earnings over 5 years: stood at -$223.1 million in 2022, then declined by 28.27% to -$286.2 million in 2023, then surged by 100.02% to $48000.0 in 2024, then gained by 27.08% to $61000.0 in 2025, then soared by 704078.69% to $429.5 million in 2026.
- The last three Retained Earnings figures came in at $429.5 million (Q1 2026), $61000.0 (Q4 2025), and -$390.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | -452.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -452.12 Mn |
| Mar 31, 2026 | 429.55 Mn |
| Dec 31, 2025 | 61,000.00 |
| Sep 30, 2025 | -390.40 Mn |
| Jun 30, 2025 | 370.47 Mn |
| Mar 31, 2025 | -355.57 Mn |
| Dec 31, 2024 | 48,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | -313.40 Mn |
| Mar 31, 2024 | 25,000.00 |
| Dec 31, 2023 | -286.17 Mn |
| Sep 30, 2023 | -275.20 Mn |
| Jun 30, 2023 | -263.48 Mn |
| Mar 31, 2023 | -240.42 Mn |
| Dec 31, 2022 | -223.09 Mn |
| Sep 30, 2022 | -200.70 Mn |
| Jun 30, 2022 | -176.78 Mn |
| Mar 31, 2022 | -155.30 Mn |
| Dec 31, 2021 | 225.54 Mn |
| Sep 30, 2021 | 222.25 Mn |